Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled KB707 in Advanced Solid Tumors Affecting the Lungs (Phase 1/2)
2025-522723-98-00Phase 2Authorised
- Sponsor
- Krystal Biotech, Inc.
- Start
- Oct 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label trial of KB707 in bronchial carcinoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Krystal Biotech, Inc. Primary endpoint: Safety (AEs and SAEs). Planned start Oct 2026; status: authorised.
02
Drugs
KB707
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522723-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522723-98-00.